Clinical Trials Using Anti-LAG-3 Monoclonal Antibody BMS-986016

Clinical trials are research studies that involve people. The clinical trials on this list are studying Anti-LAG-3 Monoclonal Antibody BMS-986016. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-18 of 18
  • An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors

    The purpose of the study is to assess the safety, tolerability and effectiveness of experimental medication BMS-986016 administered alone and in combination with nivolumab in patients with solid tumors that have spread and / or cannot be removed by surgery. The following tumor types are included in this study: Non-Small Cell Lung Cancer (NSCLC), gastric cancer, hepatocellular carcinoma, renal cell carcinoma, bladder cancer, squamous cell carcinoma of the head and neck, and melanoma, that have NOT previously been treated with immunotherapy. NSCLC and melanoma that HAVE previously been treated with immunotherapy.
    Location: 12 locations

  • A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma

    The purpose of this study is to determine whether nivolumab in combination with relatlimab is more effective than nivolumab by itself in treating unresectable melanoma or melanoma that has spread
    Location: 11 locations

  • A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer

    The purpose of this study is to determine whether Nivolumab in combination with other therapies is more effective than Nivolumab in combination with Ipilimumab in treating patients / subjects with advanced gastric cancer.
    Location: 11 locations

  • A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma

    The purpose of this study is to test the effectiveness and safety of various nivolumab combinations compared to nivolumab and ipilimumab in participants with advanced kidney cancer
    Location: 10 locations

  • Nivolumab with or without Relatlimab in Treating Advanced Esophageal or Gastric Cancer

    This phase IB trial studies how well nivolumab with or without relatlimab works in treating patients with esophageal or gastric cancer that has spread to other places in the body. Immunotherapy with monoclonal antibodies, such as nivolumab and relatlimab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
    Location: 5 locations

  • Nivolumab with or without Relatlimab before Chemoradiotherapy in Treating Patients with Operable Stage II-III Esophageal or Gastroesophageal Junction Cancer

    This phase Ib trial studies the side effects of nivolumab with or without relatlimab before chemoradiotherapy in treating patients with stage II-III esophageal or gastroesophageal junction cancer that can be removed by surgery (operable). Immunotherapy with monoclonal antibodies, such as nivolumab and relatlimab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving nivolumab with or without relatlimab prior to current chemoradiotherapy works better in treating patients with esophageal or gastroesophageal junction cancer.
    Location: 5 locations

  • A Study to Assess Safety and Efficacy of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-PD-1 Treatment

    The primary purpose of this study is to characterize the safety, tolerability, and dose-limiting toxicities (DLTs) and to determine the recommended dose of relatlimab in combination with ipilimumab (for dose escalation) and to evaluate the safety, tolerability, and preliminary efficacy of the recommended dose of relatlimab in combination with ipilimumab versus ipilimumab monotherapy (for dose expansion).
    Location: 5 locations

  • An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread

    The purpose of this study is to investigate safety and anti-tumor activity of relatlimab combination therapy in solid cancers that are advanced or have spread
    Location: 4 locations

  • Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

    This a Phase I / II randomized trial for patients with relapsed refractory Multiple Myeloma who have relapsed after treatment with prior therapies. The protocol is designed to evaluate two agents, Anti-LAG-3 and Anti-TIGIT, in order to understand their immunologic effects and safety both as single agents and in combination with pomalidomide and dexamethasone. In these arms, patients will be treated with either Anti-LAG-3 or Anti-TIGIT respectively for one cycle as single agent followed by the addition of pomalidomide and dexamethasone in combination for subsequent cycles. A third arm allows patients to be treated with the FDA approved combination of elotuzumab plus pomalidomide and dexamethsone as a control. This arm will thus allow a concurrent standard of care comparator for the experimental arms.
    Location: 3 locations

  • An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment

    The purpose of this study is to evaluate the treatment of solid tumors with various immunotherapy combinations. The treatment will be determined based upon a broad biomarker assessment.
    Location: 2 locations

  • Nivolumab and Relatlimab for the Treatment of Metastatic Uveal Melanoma

    This phase II trial studies how well nivolumab and relatlimab work in treating patients with uveal melanoma that has spread to other places in the body (metastatic). Nivolumab is thought to work by turning off the activity of PD-1 (programmed death-1), which is a protein found on T cells (a type of immune cell) that helps keep the body’s immune responses in check. When PD-1 is blocked, it is thought that the ability of T cells to kill cancer cells is increased. Relatlimab is thought to work by turning off the activity of LAG-3 (lymphocyte activation gene-3), which is a protein found on tumor infiltrating lymphocytes (TIL), a type of immune cell. When LAG-3 is blocked it is thought that TIL cell’s ability to attack cancer cells is increased, thereby reducing tumor growth. Giving nivolumab and relatlimab may increase the ability of the immune system to attack tumor cells in patients with metastatic uveal melanoma.
    Location: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida

  • Nivolumab with Relatlimab or Ipilimumab for the Treatment of Recurrent and / or Metastatic Head and Neck Squamous Cell Cancer

    This phase II trial investigates how well nivolumab with relatlimab or ipilimumab work in treating patients with head and neck squamous cell cancer that has come back (recurrent) and / or has spread to other places in the body (metastatic) and has progressed on prior immunotherapy. Immunotherapy drugs are drugs that work by trying to get the immune system to attack cancer. Comparing the immune system to a car, there are two ways to make a car go faster. One is to press on the gas pedal and the other is to take the foot of the brake. The immune system has many “gas pedals” and “brakes” in order to help it decide whether to attack or not attack. The drugs nivolumab, relatlimab, and ipilimumab are antibodies (a type of protein) that work by blocking a “brake” (akin to taking the foot off the brake in the car) on the immune system cells which can lead to the immune system attacking the cancer. Each drug blocks a different brake. Nivolumab blocks PD-1, relatlimab blocks LAG-3, and ipilimumab blocks CTLA4. Giving nivolumab together with relatlimab or ipilimumab may cause the tumor to shrink in size.
    Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania

  • A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab

    This study will characterize the movement of drugs within the body, evaluate safety and determine to which extent the body can process relatlimab in combination with nivolumab in subjects with certain advanced tumors
    Location: Hackensack University Medical Center, Hackensack, New Jersey

  • Nivolumab Alone or in Combination with Relatlimab or Ipilimumab for the Treatment of Resectable Stage III-IVA Head and Neck Cancer

    This phase II trial studies how well nivolumab alone or in combination with relatlimab or ipilimumab work in treating patients with stage III-IVA head and neck squamous cell cancer that can be removed by surgery (resectable). Immunotherapy with monoclonal antibodies, such as nivolumab, relatlimab, or ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
    Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania

  • Nivolumab and Relatlimab in Treating Patients with Stage IIIB-IV Melanoma

    This phase II trial studies how well nivolumab and relatlimab work in treating patients with stage IIIB-IV melanoma that cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab and relatlimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
    Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania

  • Nivolumab and Relatlimab in Treating Patients Microsatellite Stable Advanced Colorectal Cancer

    This phase II trial studies how well nivolumab and relatlimab work in treating patients with microsatellite stable colorectal cancer that has spread to other places in the body. Microsatellites are short pieces of genetic materials that are repeated together in a row along the DNA molecule. In some colon tumors the number of microsatellite repeats is different that the number of repeats in the DNA when it was inherited, which might be due to DNA repair defects in these tumors. Microsatellite stable tumors do not have this defect. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Relatlimab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving nivolumab and relatlimab may work better in treating patients with microsatellite stable colorectal cancer that has spread to other places in the body.
    Location: Johns Hopkins University / Sidney Kimmel Cancer Center, Baltimore, Maryland

  • Nivolumab and Relatlimab in Treating Patients with Advanced Chordoma

    This phase II trial studies how well nivolumab and relatlimab work in treating patients with chordoma that has spread to other places in the body. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Relatlimab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread.
    Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

  • Nivolumab and Relatlimab in Treating Patients with Locally Advanced or Metastatic Mismatch Repair Deficient Solid Tumors Resistant to Prior PD-L1 Therapy

    This phase II trial studies how well nivolumab and relatlimab work in treating patients with mismatch repair deficient solid tumors that have spread from where they started to nearby tissue or lymph nodes (locally advanced) or other places in the body (metastatic) and are resistant to prior PD-L1 therapy. Immunotherapy with monoclonal antibodies, such as nivolumab and relatlimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
    Location: Johns Hopkins University / Sidney Kimmel Cancer Center, Baltimore, Maryland